Teclistamab,Daratumumab,Pomalidomide,Lenalidomide,Bortezomib,Nirogacestat
Genmab,Janssen,springworks therapeutics,Takeda,bms
['mmsm', ' clad ']
tec-dara-len with 90.6 % all grade infection will be difficult to manage and resulting in treatment delays and dose reductions #ash22 #mmsm 
Director of the Myeloma & Amyloidosis Service @columbiacancer - Associate Editor @JCO_ASCO-Tweets are my own
https://t.co/eoOACqg46y